Stocktoria
Gossamer Bio, Inc. GOSS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-02-08
Gossamer Bio, Inc. statistics & valuation
Market cap$76.7M
P / S1.6×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -352.2% | -52.2% | — | — | — |
| Net margin | -351.5% | -49.3% | — | — | — |
| FCF margin | -353.5% | -3.0% | — | — | — |
| Return on assets | -98.9% | -17.9% | -57.6% | -84.2% | -68.1% |
| Return on equity | 138.8% | -191.7% | -286.5% | -1899.3% | -192.7% |
| Debt / equity | — | 0.00× | 0.01× | 0.99× | 0.24× |
| Current ratio | 2.64 | 6.88 | 5.94 | 5.32 | 8.32 |
| Revenue growth | -57.7% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001728117 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.